BTRC and cancer: The fact that NRF2 in cancer cells can acquire point mutations at multiple sites for gain of stability in its functional domains (e.g., interfaces to KEAP1 or β−TRCP), such gain of function by mutated NRF2 contributes to the survival of abnormal cells and finally, tumor/cancer following input from additional oncogenic pressures.